PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Urogenital tract microbes (genus: Lactobacillus) decrease Metronidazole's activity.
Urogenital tract
Metronidazole (PubChem CID: 4173)
Lactobacillus (Tax ID: 1578)
decrease activity
metronidazole is the nitroimidazole antibiotic and antiprotozoal drug used to treat bacterial vaginosis and pelvic inflammatory disease. The pre-treatment state of the microbiota community inside the vagina widely affects the drug action and the rate of recurrence. An ordinary differential equation model is used to predict metronidazole action and fate and bacterial growth. the model shows the high abundance of Lactobacillus, before metronidazole treatment, decreases metronidazole efficiency. A clinical cohort trial was done to approve the results in women with recurrent vaginosis showed that the women have a higher abundance of Lactobacillus.

Browse Drug-Microbiome Relationship